ATE350396T1 - Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung - Google Patents
Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendungInfo
- Publication number
- ATE350396T1 ATE350396T1 AT02726037T AT02726037T ATE350396T1 AT E350396 T1 ATE350396 T1 AT E350396T1 AT 02726037 T AT02726037 T AT 02726037T AT 02726037 T AT02726037 T AT 02726037T AT E350396 T1 ATE350396 T1 AT E350396T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides derived
- medical use
- neurofilament proteins
- proteins
- neurofilament
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29315601P | 2001-05-25 | 2001-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE350396T1 true ATE350396T1 (de) | 2007-01-15 |
Family
ID=23127882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02726037T ATE350396T1 (de) | 2001-05-25 | 2002-05-24 | Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US6924266B2 (https=) |
| EP (1) | EP1390403B1 (https=) |
| JP (1) | JP4584573B2 (https=) |
| KR (1) | KR100945383B1 (https=) |
| CN (1) | CN1582301A (https=) |
| AT (1) | ATE350396T1 (https=) |
| AU (1) | AU2002256587B2 (https=) |
| BR (1) | BR0209990A (https=) |
| CA (1) | CA2448348C (https=) |
| CY (1) | CY1111120T1 (https=) |
| DE (1) | DE60217326T2 (https=) |
| DK (1) | DK1390403T3 (https=) |
| ES (1) | ES2278916T3 (https=) |
| NO (1) | NO334189B1 (https=) |
| NZ (1) | NZ529911A (https=) |
| PT (1) | PT1390403E (https=) |
| WO (1) | WO2002097030A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002304314B2 (en) * | 2001-03-08 | 2007-09-06 | Nyomox Pharmaceutical Corporation | Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| IL159903A0 (en) * | 2001-07-19 | 2004-06-20 | Nymox Corp | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| EP1847550A3 (en) * | 2001-07-19 | 2008-01-09 | Nymox Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| US7317077B2 (en) | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| CA2555306A1 (en) * | 2004-02-06 | 2005-08-18 | Nymox Corporation | Humanized antibody |
| WO2005089398A2 (en) * | 2004-03-18 | 2005-09-29 | St. Luke's Hospital | Method for the delivery of sustained release agents |
| EA200801942A1 (ru) * | 2006-03-10 | 2009-02-27 | Наймокс Корпорейшн | Способ предотвращения или уменьшения риска возникновения рака с использованием пептидов на основе белков нервных волокон |
| CN101215323B (zh) * | 2007-12-28 | 2011-11-30 | 首都医科大学宣武医院 | 人ad7c-ntp抗原决定簇多肽、抗体及其在诊断试剂盒上的应用 |
| US20160361380A1 (en) | 2015-06-12 | 2016-12-15 | Nymox Corporation | Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations |
| US11628202B2 (en) | 2015-07-24 | 2023-04-18 | Nymox Corporation | Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia |
| US10183058B2 (en) | 2016-06-17 | 2019-01-22 | Nymox Corporation | Method of preventing or reducing the progression of prostate cancer |
| US10172910B2 (en) | 2016-07-28 | 2019-01-08 | Nymox Corporation | Method of preventing or reducing the incidence of acute urinary retention |
| US10532081B2 (en) | 2016-09-07 | 2020-01-14 | Nymox Corporation | Method of ameliorating or preventing the worsening or the progression of symptoms of BPH |
| US10335453B2 (en) | 2017-03-01 | 2019-07-02 | Nymox Corporation | Compositions and methods for improving sexual function |
| US10835538B2 (en) | 2018-03-28 | 2020-11-17 | Nymox Corporation | Method of treating benign prostatic hyperlasia with antibiotics |
| US20200061150A1 (en) | 2018-08-23 | 2020-02-27 | Nymox Corporation | Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function |
| US20200360466A1 (en) | 2019-05-13 | 2020-11-19 | Nymox Corporation | Method of improving lower urinary tract symptoms |
| US11298400B2 (en) | 2019-05-13 | 2022-04-12 | Nymox Corporation | Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS |
| US11278588B2 (en) | 2019-05-13 | 2022-03-22 | Nymox Corporation | Method of treating lower urinary tract symptoms with fexapotide triflutate |
| US11231421B2 (en) | 2019-07-31 | 2022-01-25 | Nymox Corporation | Methods of treating multifocal cancer |
| US11331374B2 (en) | 2019-07-31 | 2022-05-17 | Nymox Corporation | Focal treatment of prostate cancer |
| CN111579799A (zh) * | 2020-06-23 | 2020-08-25 | 江苏省荣军医院 | 一种检测尿液中阿尔茨海默病相关神经丝蛋白的荧光免疫层析试纸的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990006993A1 (en) * | 1988-12-21 | 1990-06-28 | The General Hospital Corporation | Method of detecting neurological disease or dysfunction |
| US5948634A (en) * | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| CA2282729A1 (en) * | 1997-02-26 | 1998-09-03 | The General Hospital Corporation | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease |
| WO1999019347A1 (en) | 1997-10-10 | 1999-04-22 | Astrazeneca Ab | Synthetic genes with immunomodulatory effects |
| AU765110B2 (en) * | 1998-06-26 | 2003-09-11 | Georgetown University Medical Center | Compositions and methods for inducing cell death |
| AU2185199A (en) * | 1998-09-30 | 2000-04-17 | Yoko Aida | Apoptosis inducers |
| AU2373800A (en) | 1998-12-11 | 2000-06-26 | Incyte Pharmaceuticals, Inc. | Neuron-associated proteins |
| DE60003632T2 (de) * | 1999-01-11 | 2004-04-15 | Leadd B.V. | Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten |
| WO2000063230A2 (en) * | 1999-03-26 | 2000-10-26 | Human Genome Sciences, Inc. | 49 human secreted proteins |
| AU3769700A (en) | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | 45 human secreted proteins |
| US7259232B1 (en) | 2000-10-27 | 2007-08-21 | Nymox Pharmaceutical Corporation | Preferred segments of neural thread protein |
| AU2002304314B2 (en) | 2001-03-08 | 2007-09-06 | Nyomox Pharmaceutical Corporation | Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| DK1392347T3 (da) | 2001-05-16 | 2005-12-12 | Nymox Corp | Fremgangsmåde til at forhindre celledöd med anvendelse af segmenter af neurale trådproteiner |
-
2002
- 2002-05-24 DK DK02726037T patent/DK1390403T3/da active
- 2002-05-24 ES ES02726037T patent/ES2278916T3/es not_active Expired - Lifetime
- 2002-05-24 WO PCT/CA2002/000759 patent/WO2002097030A2/en not_active Ceased
- 2002-05-24 KR KR1020037015376A patent/KR100945383B1/ko not_active Expired - Fee Related
- 2002-05-24 CN CNA028149777A patent/CN1582301A/zh active Pending
- 2002-05-24 DE DE60217326T patent/DE60217326T2/de not_active Expired - Lifetime
- 2002-05-24 AT AT02726037T patent/ATE350396T1/de active
- 2002-05-24 PT PT02726037T patent/PT1390403E/pt unknown
- 2002-05-24 EP EP02726037A patent/EP1390403B1/en not_active Expired - Lifetime
- 2002-05-24 BR BR0209990-0A patent/BR0209990A/pt not_active IP Right Cessation
- 2002-05-24 NZ NZ529911A patent/NZ529911A/en not_active IP Right Cessation
- 2002-05-24 US US10/153,334 patent/US6924266B2/en not_active Expired - Fee Related
- 2002-05-24 AU AU2002256587A patent/AU2002256587B2/en not_active Ceased
- 2002-05-24 CA CA2448348A patent/CA2448348C/en not_active Expired - Fee Related
- 2002-05-24 JP JP2003500199A patent/JP4584573B2/ja not_active Expired - Fee Related
-
2003
- 2003-11-25 NO NO20035231A patent/NO334189B1/no not_active IP Right Cessation
-
2007
- 2007-03-12 CY CY20071100339T patent/CY1111120T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2448348A1 (en) | 2002-12-05 |
| NO334189B1 (no) | 2014-01-13 |
| KR20040038913A (ko) | 2004-05-08 |
| CN1582301A (zh) | 2005-02-16 |
| EP1390403A2 (en) | 2004-02-25 |
| EP1390403B1 (en) | 2007-01-03 |
| CY1111120T1 (el) | 2015-06-11 |
| NO20035231D0 (no) | 2003-11-25 |
| ES2278916T3 (es) | 2007-08-16 |
| US20030096350A1 (en) | 2003-05-22 |
| AU2002256587B2 (en) | 2008-04-03 |
| JP2004534533A (ja) | 2004-11-18 |
| DK1390403T3 (da) | 2007-05-14 |
| US6924266B2 (en) | 2005-08-02 |
| PT1390403E (pt) | 2007-03-30 |
| KR100945383B1 (ko) | 2010-03-05 |
| BR0209990A (pt) | 2004-06-29 |
| DE60217326T2 (de) | 2007-10-18 |
| WO2002097030A3 (en) | 2003-10-30 |
| NO20035231L (no) | 2004-01-26 |
| JP4584573B2 (ja) | 2010-11-24 |
| DE60217326D1 (de) | 2007-02-15 |
| NZ529911A (en) | 2008-05-30 |
| WO2002097030A2 (en) | 2002-12-05 |
| CA2448348C (en) | 2013-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111120T1 (el) | Πεπτιδια που παραγονται απο πρωτεϊνες νευρικων ινων και η ιατρικη τους χρηση | |
| CY1107578T1 (el) | Πεπτιδια που χρησιμευουν στη θepαπεια ογκων και αλλων καταστασεων που χρηζουν την αφαιρεση ή την καταστροφη κυτταρων | |
| EA200400205A1 (ru) | Пептиды, эффективные в лечении опухолей и других заболеваний, требующих удаления или разрушения клеток | |
| CY1109650T1 (el) | Χρηση νευρικων νηματικων πρωτεϊνων για την αντιμετωπιση νεοπλασιων | |
| DE69533855D1 (de) | UNTERBRECHUNG DER BINDUNG DER PROTEINE MDM2 UND p53 UND ENTSPRECHENDE THERAPEUTISCHE ANWENDUNG | |
| ATE230417T1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
| ATE443076T1 (de) | Von protease typ ii spaltbares peptid | |
| EA200001124A1 (ru) | Способ генной терапии | |
| DK1438329T3 (da) | Biologisk aktive peptider og deres anvendelse til reparation af beskadigede nerver | |
| EP1714979A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
| EP1847550A3 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1390403 Country of ref document: EP |